文献速递消化内镜胃肠动力与功能性疾病

胰高血糖素样肽-1受体激动剂增加上消化道内镜检查中固体胃残留率,尤其在糖尿病并发症患者中:一项病例对照研究

Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
PubMed 文献 · Am J Gastroenterol · 2024-03-27

这项回顾性病例对照研究比较了306例使用胰高血糖素样肽-1受体激动剂(GLP-1RA)的患者与倾向性评分匹配的对照在上消化道内镜检查中胃残留的频率,发现GLP-1RA使用者胃残留率显著更高(14% vs 4%,P < 0.01),尤其在2型糖尿病(T2DM)、胰岛素依赖和T2DM并发症患者中;延长禁食和清流质饮食以及下午操作与较低胃残留率相关;尽管22%胃残留患者需要插管、25%提前终止操作,但未记录到操作并发症或误吸。

要点

  • GLP-1RA使用者上消化道内镜胃残留率显著高于匹配对照(14% vs 4%,P < 0.01)。
  • T2DM并发症患者胃残留风险最高,延长禁食和清流质饮食与较低残留率相关。
  • 胃残留患者中22%需插管、25%提前终止操作,但未记录操作并发症或误吸。

核心结论

  • GLP-1RA使用与上消化道内镜胃残留增加相关,尤其在T2DM患者中,其影响超过单独阿片类药物的影响。
  • 存在T2DM并发症时风险最高,而延长禁食和清流质饮食具有保护作用。
  • 胃残留风险增加似乎并未转化为操作并发症风险增加。

研究设计与样本

  • 回顾性病例对照研究,连续纳入3.5年期间接受内镜操作的患者。
  • 比较306例GLP-1RA使用者与倾向性评分匹配对照的胃残留频率。
  • 内镜前未停用GLP-1RA。
  • 通过审查内镜报告和图像评估胃残留。

主要发现

  • GLP-1RA使用者胃残留率显著高于匹配对照(14% vs 4%,P < 0.01)。
  • T2DM患者中胃残留率为14% vs 4%(P < 0.01)。
  • 胰岛素依赖患者中胃残留率为17% vs 5%(P < 0.01)。
  • T2DM并发症患者中胃残留率为15% vs 2%(P < 0.01)。
  • 同时行结肠镜检查前延长禁食和清流质饮食者胃残留率较低(2% vs 11%,P < 0.01),下午操作者胃残留率较低(4% vs 11%,P < 0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) prescribed for weight loss and type 2 diabetes mellitus (T2DM) can delay gastric emptying, but risk factors and impact on procedure outcomes remain unclear. METHODS: We compared frequency of gastric residue on upper endoscopy in patients on a GLP-1RA and propensity score-matched controls in this retrospective case-control study of consecutive patients undergoing endoscopic procedures over a 3.5-year period. GLP-1RAs were not held before endoscopy. The gastric residue presence was assessed by reviewing endoscopy reports and images. Predictors and consequences of gastric residue with GLP-1RA were determined. RESULTS: In 306 GLP-1RA users compared with matched controls, rates of gastric residue were significantly higher with GLP-1RA use (14% vs 4%, P < 0.01), especially in patients with T2DM (14% vs 4%, P < 0.01), with insulin dependence (17% vs 5%, P < 0.01) and T2DM complications (15% vs 2%, P < 0.01). Lower gastric residue rates were noted after prolonged fasting and clear liquids for concurrent colonoscopy (2% vs 11%, P < 0.01) and in patients with afternoon procedures (4% vs 11%, P < 0.01). While 22% with gastric residue required intubation and 25% had early procedure termination, no procedural complications or aspiration were recorded. DISCUSSION: GLP-1RA use is associated with increased gastric residue on upper endoscopy, particularly in patients with T2DM, surpassing the impact of opiates alone. Risk is highest in the presence of T2DM complications while prolonged fasting and a clear-liquid diet are protective. This increased risk of gastric residue does not appear to translate to an increased risk of procedural complications.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Garza K, Aminpour E, Shah J, et al. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study. Am J Gastroenterol. 2024. PMID: 38534127. doi:10.14309/ajg.0000000000002777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。